Corrigendum to ‘Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)’ [Gynecologic Oncology Reports 31 (2020) 100532]

Publication date: Available online 28 May 2020Source: Gynecologic Oncology ReportsAuthor(s): Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Roisin O'Cearbhaill, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael J. Birrer
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research